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Poster Session II 117the resulting GFP1Vb141 T cells comprised 3–4% of the PBMC,
but were .98% CD81. These results suggest that while the TCR
on the transduced cells predisposes their development to the CD4
lineage, it does not absolutely preclude CD8 lineage differentiation.
Importantly, GFP1 cells from BALB. B-primed B6 mice, which had
been administered bone marrow cells transduced with the Vb14-
Jb2.4 TCR construct, exhibited anti-BALB. B reactivity in an
IFNg ELISPOT system. On the other hand, GFP1Vb141 T cells
from primed mice receiving marrow cells transduced with a control
vector expressing Vb14-Jb2.3 TCR, did not show anti anti-BALB.
B reactivity. This bone marrow TCR transduction system can be
used to investigate the development and reactivity of T cells ex-
pressing specific TCRb receptors.317
IMPACT OF PROPHYLACTIC RED BLOOD CELL EXCHANGE FOR PREVEN-
TION OF SEVERE IMMUNE HEMOLYSIS IN PEDIATRIC MINOR ABO-MIS-
MATCHED ALLOGENEIC PERIPHERAL BLOOD PROGENITOR CELL
TRANSPLANTATION
Bolotin, E., Rosenthal, J., Pawlowska, A., Falk, P., Wang, S., Hitt, D.,
Friday, J., Forman, S. City of Hope National Medical Center and Beck-
man Research Institute, Duarte, CA.
The presence of minor ABO incompatibility between donor and
recipient is common in allogeneic hematopoietic stem cell trans-
plantation (allo-HSCT). Delayed severe immune hemolysis due
to donor-derived passenger lymphocytes has been reported in mi-
nor and/or bidirectional ABO-mismatched transplants. To evaluate
the impact of RBC exchange procedure in pediatric patients on the
morbidity and outcome we analyzed 29 pediatric cases undergoing
minor ABO-incompatible allo-HSCT from January 2000 to Janu-
ary 2007. First group (RBC exchange) included sixteen patients
who underwent prophylactic red cell exchange. Six patients received
grafts from HLA identical siblings, ten patients – from HLA
matched unrelated donors. Eleven patients received bone marrow
transplant (BMT), five patients received peripheral stem cell trans-
plant (PBSC). Patient’s age was 10 6 5.3 years old.
Second group (No – RBC exchange) included thirteen patients
who did not undergo prophylactic red cell exchange, but the stem
cell product was plasma depleted according to the institutional
guidelines. Six patients received grafts from HLA identical siblings,
three patients from HLA matched unrelated donors, and four pa-
tients form unrelated cord blood. Four patients received BMT,
five patients received PBSC, four patients received cord blood
transplant. Patient’s age was 7.6 6 5.4 years old.
No incidence of immune mediated hemolysis was documented in
both groups. No patients developed pure red cell aplasia. RBC en-
graftment was not different in both groups (23.26 4.2 vs. 226 4.2
days). Neutrophil engraftment was similar in both groups (21.0 6
5.4 vs. 21.026 4.0 days). No significant difference was found among
the groups in the incidence of acute graft vs. host disease (GVHD).
The incidence of chronic GVHD was insignificantly higher in pa-
tients with no RBC exchange (72% vs. 60%). The relapse rate
and overall outcome were not influence.
In conclusion these results suggest that RBC exchange does not
have a significant impact in pediatric patients. Further investiga-
tions are required to identify the best clinical transfusion practice
in pediatric patients with minor ABO incompatibility.318
BUSULFAN, FLUDARABINE AND TOTAL BODY IRRADIATION FOLLOWED
BY ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
IS AN EFFECTIVE TREATMENT FOR HEMATOLOGIC MALIGNANCIES
WITH ACCEPTABLE TOXICITY IN A HIGHER-RISK POPULATION
Meyers, G., Dunn, A., Kovacsovics, T., Fleming, W., Epner, E., Hayes-
Lattin, B., Mauro, M., Deininger, M., Bubalo, J., Maziarz, R. Oregon
Health and Science University, Portland, OR.Reduced-intensity conditioning regimens followed by allogeneic
peripheral blood stem cell transplantation are a feasible treatment
program for elderly patients with hematologic malignancies and
those who have relapsed after an autologous bone marrow trans-
plant. Optimization of the conditioning regimen to promote disease
control, engraftment, and rapid escalation of donor chimerisms
without compromising treatment-related toxicity was the goal in
our institutional protocol of busulfan 3.2 mg/kg intravenously, flu-
darabine 90 mg/m2, and total body irradiation 200cGy followed by
infusion of allogeneic peripheral blood stem cells. We report the re-
sults of 47 patients treated on this protocol since August 2005. The
treatment cohort included patients with a median age of 62 years
(range 24–74), with 24 patients with myeloid diseases and 23 with
lymphoid diseases. In 14 patients this was a second transplant. Do-
nors included 11 sibling donors and 36 matched unrelated donors
with five with a single-antigen mismatch. At the time of this report,
27 patients are alive, with a median follow-up of 240 days (range 32–
804). Engraftment occurred in all but one patient, and lymphoid
and myeloid donor chimerisms revealed early and stable engraft-
ment. See Table 1 for demographics, chimerism findings, and treat-
ment complications. Kaplan-Meier (K-M) incidence of 1-year non-
relapse mortality was 31% and K-M incidence of relapse was 40%.
The K-M incidence of Grade II-IV Acute GVHD was 71%, with
27.7% Grade III-IV. The K-M incidence of extensive chronic
GVHD was 80%. K-M estimate of long-term overall survival was
36%, with a 1-year survival of 49%. When comparing myeloid vs.
lymphoid diseases, the K-M estimate of long-term progression-
free survival of myeloid diseases was significantly higher at 31%
compared to 19% for lymphoid diseases. In conclusion, our institu-
tional protocol of busulfan, fludarabine and TBI followed by alloge-
neic peripheral blood stem cell transplant shows acceptable toxicity
and overall outcomes in this higher-risk group. Disease relapse sig-
nificantly impacts outcomes in this cohort, and future research will
focus on optimizing disease control.Table 1.Age Mean 60.7 years (range
24–74)Males/Females 33/14
Diseases
AML 20
CML 2
MDS 2
ALL 2
CLL 4
HD 2
MM 4
NHL 9
PLL 1
Waldenstrom’s 1
Previous Auto/Allo 13/1
Sibling Allo/MUD 11/36CD31/CD331
ChimerismsMedianDay1 28 CD31/CD331 79.5%/100%
Day1 56 CD31/CD331 89%/100%
Day1 84 CD31/CD331 90%/100%
Primary Cause of Death N 5 20
Acute GVHD 2
Chronic GVHD 1
Graft Failure 1
Bacterial Infection 2
Fungal Infection 1
Viral Infection 1
Idiopathic Interstitial
Pneumonia1Cardiomyopathy 1
Multiple Organ Failure 1
Recurrent/Persistent
Disease8Thromboembolic 1
